|
1
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: data
from the Surveillance, Epidemiology, and End Results Program.
Cancer. 115:1531–1543. 2009.
|
|
2
|
Akiyama T, Dass CR and Choong PF: Novel
therapeutic strategy for osteosarcoma targeting osteoclast
differentiation, bone-resorbing activity, and apoptosis pathway.
Mol Cancer Ther. 7:3461–3469. 2008.
|
|
3
|
Inamdar GS, Madhunapantula SV and
Robertson GP: Targeting the MAPK pathway in melanoma: why some
approaches succeed and other fail. Biochem Pharmacol. 80:624–637.
2010.
|
|
4
|
McCubrey JA, Steelman LS, Abrams SL, et
al: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in
malignant transformation and drug resistance. Adv Enzyme Regul.
46:249–279. 2006.
|
|
5
|
McCubrey JA, Steelman LS, Chappell WH, et
al: Roles of the Raf/MEK/ERK pathway in cell growth, malignant
transformation and drug resistance. Biochim Biophys Acta.
1773:1263–1284. 2007.
|
|
6
|
Eisenmann KM, van Brocklin MW, Staffend
NA, Kitchen SM and Koo HM: Mitogen-activated protein kinase
pathway-dependent tumor-specific survival signaling in melanoma
cells through inactivation of the proapoptotic protein bad. Cancer
Res. 63:8330–8337. 2003.
|
|
7
|
Satyamoorthy K, Li G, Gerrero MR, et al:
Constitutive mitogen-activated protein kinase activation in
melanoma is mediated by both BRAF mutations and autocrine growth
factor stimulation. Cancer Res. 63:756–759. 2003.
|
|
8
|
Chen L, Shi Y, Jiang CY, Wei LX, Wang YL
and Dai GH: Expression and prognostic role of pan-Ras, Raf-1, pMEK1
and pERK1/2 in patients with hepatocellular carcinoma. Eur J Surg
Oncol. 37:513–520. 2011.
|
|
9
|
Barry OP, Mullan B, Sheehan D, et al:
Constitutive ERK1/2 activation in esophagogastric rib bone marrow
micrometastatic cells is MEK-independent. J Biol Chem.
276:15537–15546. 2001.
|
|
10
|
Sivaraman VS, Wang H, Nuovo GJ and Malbon
CC: Hyperexpression of mitogen-activated protein kinase in human
breast cancer. J Clin Invest. 99:1478–1483. 1997.
|
|
11
|
Oka H, Chatani Y, Hoshino R, et al:
Constitutive activation of mitogen-activated protein (MAP) kinases
in human renal cell carcinoma. Cancer Res. 55:4182–4187. 1995.
|
|
12
|
Gregorj C, Ricciardi MR, Petrucci MT, et
al: ERK1/2 phosphorylation is an independent predictor of complete
remission in newly diagnosed adult acute lymphoblastic leukemia.
Blood. 109:5473–5476. 2007.
|
|
13
|
Sridhar SS, Hedley D and Siu LL: Raf
kinase as a target for anticancer therapeutics. Mol Cancer Ther.
4:677–685. 2005.
|
|
14
|
Yang R, Piperdi S and Gorlick R:
Activation of the RAF/mitogen-activated protein/extracellular
signal-regulated kinase kinase/extracellular signal-regulated
kinase pathway mediates apoptosis induced by chelerythrine in
osteosarcoma. Clin Cancer Res. 14:6396–6404. 2008.
|
|
15
|
Shimo T, Matsumura S, Ibaragi S, et al:
Specific inhibitor of MEK-mediated cross-talk between ERK and p38
MAPK during differentiation of human osteosarcoma cells. J Cell
Commun Signal. 1:103–111. 2007.
|
|
16
|
Bass BL: Double-stranded RNA as a template
for gene silencing. Cell. 101:235–238. 2000.
|
|
17
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008.
|
|
18
|
Iwagaki A, Choe N, Li Y, Hemenway DR and
Kagan E: Asbestos inhalation induces tyrosine nitration associated
with extracellular signal-regulated kinase 1/2 activation in the
rat lung. Am J Respir Cell Mol Biol. 28:51–60. 2003.
|
|
19
|
Van Golen KL, Wu ZF, Qiao XT, Bao LW and
Merajver SD: RhoC GTPase, a novel transforming oncogene for human
mammary epithelial cells that partially recapitulates the
inflammatory breast cancer phenotype. Cancer Res. 60:5832–5838.
2000.
|
|
20
|
Lin JC, Chang SY, Hsieh DS, Lee CF and Yu
DS: Modulation of mitogen-activated protein kinase cascades by
differentiation-1 protein: acquired drug resistance of hormone
independent prostate cancer cells. J Urol. 174:2022–2026. 2005.
|
|
21
|
Zhang D, LaFortune TA, Krishnamurthy S, et
al: Epidermal growth factor receptor tyrosine kinase inhibitor
reverses mesenchymal to epithelial phenotype and inhibits
metastasis in inflammatory breast cancer. Clin Cancer Res.
15:6639–6648. 2009.
|
|
22
|
Bacci G, Longhi A, Versari M, Mercuri M,
Briccoli A and Picci P: Prognostic factors for osteosarcoma of the
extremity treated with neoadjuvant chemotherapy: 15-year experience
in 789 patients treated at a single institution. Cancer.
106:1154–1161. 2006.
|
|
23
|
Roberts PJ and Der CJ: Targeting the
Raf-MEK-ERK mitogen-activated protein kinase cascade for the
treatment of cancer. Oncogene. 26:3291–3310. 2007.
|
|
24
|
Montagut C and Settleman J: Targeting the
RAF-MEK-ERK pathway in cancer therapy. Cancer Lett. 283:125–134.
2009.
|
|
25
|
Friday BB and Adjei AA: Advances in
targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase
cascade with MEK inhibitors for cancer therapy. Clin Cancer Res.
14:342–346. 2008.
|
|
26
|
Gailhouste L, Ezan F, Bessard A, et al:
RNAi-mediated MEK1 knock-down prevents ERK1/2 activation and
abolishes human hepatocarcinoma growth in vitro and in vivo. Int J
Cancer. 126:1367–1377. 2010.
|
|
27
|
Zeng P, Wagoner HA, Pescovitz OH and
Steinmetz R: RNA interference (RNAi) for extracellular
signal-regulated kinase 1 (ERK1) alone is sufficient to suppress
cell viability in ovarian cancer cells. Cancer Biol Ther.
4:961–967. 2005.
|
|
28
|
Koul S, Huang M, Chaturvedi L, Meacham RB
and Koul HK: p42/p44 mitogen-activated protein kinase signal
transduction pathway regulates interleukin-6 expression in PC3
cells, a line of hormone-refractory prostate cancer cells. Ann NY
Acad Sci. 1030:253–257. 2004.
|
|
29
|
Liu L, Cao Y, Chen C, et al: Sorafenib
blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and
induces tumor cell apoptosis in hepatocellular carcinoma model
PLC/PRF/5. Cancer Res. 66:11851–11858. 2006.
|
|
30
|
Janmaat ML, Rodriguez JA, Gallegos-Ruiz M,
Kruyt FA and Giaccone G: Enhanced cytotoxicity induced by gefitinib
and specific inhibitors of the Ras or phosphatidyl inositol-3
kinase pathways in non-small cell lung cancer cells. Int J Cancer.
118:209–214. 2006.
|
|
31
|
Lapteva N, Yang AG, Sanders DE, Strube RW
and Chen SY: CXCR4 knockdown by small interfering RNA abrogates
breast tumor growth in vivo. Cancer Gene Ther. 12:84–89. 2005.
|
|
32
|
Susa M, Iyer AK, Ryu K, et al: Inhibition
of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery
system to overcome drug resistance in osteosarcoma. PLoS One.
5:e107642010.
|
|
33
|
Pignochino Y, Grignani G, Cavalloni G, et
al: Sorafenib blocks tumour growth, angiogenesis and metastatic
potential in preclinical models of osteosarcoma through a mechanism
potentially involving the inhibition of ERK1/2, MCL-1 and ezrin
pathways. Mol Cancer. 8:1182009.
|
|
34
|
Do SI, Jung WW, Kim HS and Park YK: The
expression of epidermal growth factor receptor and its downstream
signaling molecules in osteosarcoma. Int J Oncol. 34:797–803.
2009.
|
|
35
|
Gysin S, Lee SH, Dean NM and McMahon M:
Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits
pancreatic cancer cell cycle arrest through induced expression of
p27Kip1. Cancer Res. 65:4870–4880. 2005.
|
|
36
|
Sutter AP, Maaser K, Gerst B, Krahn A,
Zeitz M and Scherubl H: Enhancement of peripheral benzodiazepine
receptor ligand-induced apoptosis and cell cycle arrest of
esophageal cancer cells by simultaneous inhibition of MAPK/ERK
kinase. Biochem Pharmacol. 67:1701–1710. 2004.
|
|
37
|
Shukla A, Hillegass JM, Macpherson MB, et
al: ERK2 is essential for the growth of human epithelioid malignant
mesotheliomas. Int J Cancer. 129:1075–1086. 2011.
|
|
38
|
Chen H, Zhu G, Li Y, et al: Extracellular
signal-regulated kinase signaling pathway regulates breast cancer
cell migration by maintaining slug expression. Cancer Res.
69:9228–9235. 2009.
|
|
39
|
Pellicano F, Simara P, Sinclair A, et al:
The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in
CD34+ CML stem/progenitor cells. Leukemia. 25:1159–1167.
2011.
|
|
40
|
Trisciuoglio D, Iervolino A, Zupi G and
Del Bufalo D: Involvement of PI3K and MAPK signaling in
bcl-2-induced vascular endothelial growth factor expression in
melanoma cells. Mol Biol Cell. 16:4153–4162. 2005.
|
|
41
|
Zamble DB and Lippard SJ: Cisplatin and
DNA repair in cancer chemotherapy. Trends Biochem Sci. 20:435–439.
1995.
|
|
42
|
Mandic A, Viktorsson K, Heiden T, Hansson
J and Shoshan MC: The MEK1 inhibitor PD98059 sensitizes C8161
melanoma cells to cisplatin-induced apoptosis. Melanoma Res.
11:11–19. 2001.
|
|
43
|
Lu Y and Cederbaum A: The mode of
cisplatin-induced cell death in CYP2E1-overexpressing HepG2 cells:
modulation by ERK, ROS, glutathione, and thioredoxin. Free Radic
Biol Med. 43:1061–1075. 2007.
|
|
44
|
Wang J, Zhou JY and Wu GS: ERK-dependent
MKP-1-mediated cisplatin resistance in human ovarian cancer cells.
Cancer Res. 67:11933–11941. 2007.
|
